New Medical Therapies -- Lung Cancer articles from January 1 2000

New Medical Therapies -- Lung Cancer archives from January 1 2000

Lung Cancer.(Pamphlet)
January 1, 2000... Clinical Research Focuses on Chemotherapy and Vaccines LUNG CANCER ACCOUNTS FOR ALMOST 15% of all cancer cases, making it one of the most common cancers in the United States. Each year, 170,000 new cases of this disease are diagnosed....

Clinical Research Focuses on Chemotherapy and Vaccines.
January 1, 2000... LUNG CANCER ACCOUNTS FOR ALMOST 15% of all cancer cases, making it one of the most common cancers in the United States. Each year, 170,000 new cases of this disease are diagnosed. Lung cancer research is highly active due to the seriousness...

Investigating Your Treatment Options.
January 1, 2000... YOU OR SOMEONE YOU CARE ABOUT MAY recently have been diagnosed with lung cancer. In addition to dealing with many personal and emotional issues, you want to receive the best treatment available. New Medical Therapies: REPORT ON LUNG CANCER is...

Why Women are More Likely to Develop Lung Cancer.
January 1, 2000... A gene linked to abnormal cell growth in the lung is more active in women than in men, a discovery that may explain why female smokers are more than twice as likely to develop lung cancer as males who smoke. The gene called gastrin-releasing...

Making Tumors Susceptible to Treatment.
January 1, 2000... The National Cancer Institute (NCI) recently began a phase I/II study of the anticancer compound, G3139, at the University of Chicago Medical Center and Ohio State University Hospital. The study will use G 3139 in combination with paclitaxel...

Breast Cancer Drug Expanded to Treat Lung Cancer.(Taxotere)
January 1, 2000... The FDA recently expanded the approval of the breast cancer drug Taxotere (docetaxel) to include the treatment of some patients with advanced lung cancer. It can be used to treat patients with non-small cell lung cancer that is locally...

Gene Could Lead to New Drug.(EGFL6)
January 1, 2000... New results indicate that a gene, EGFL6, is selectively expressed in lung tumor tissue, but not in normal lung tissue. This makes the gene and its expressed protein potential candidates for pharmaceutical drug development and lung cancer...

Phase III Trials Will Begin for VEGF.(Vascular Endothelial Growth Factor)
January 1, 2000... After meeting phase II clinical trial objectives, Genentech will proceed with phase III trials in the development of its recombinant humanized monoclonal antibody to Vascular Endothelial Growth Factor (rhuMab-VEGF) in combination with...

Combination Therapy Proves Effective.
January 1, 2000... Researchers at the METAXAS Memorial Cancer Hospital in Greece conducted a phase II study of the three most active single chemotherapeutic agents in advanced non-small cell lung cancer (NSCLC). The researchers used a combination of docetaxel,...

Oral Drug Evaluated.(JM216)
January 1, 2000... A phase II study to evaluate tumor tolerance of an oral platinum drug JM216 determined that it is an active first-line treatment in patients with small-cell lung cancer. The oral drug was given to patients who had extensive disease or were...

Need for Improved Prevention and Treatment.
January 1, 2000... A 10-year survey of lung cancer treatment and survival rates in hospitals in the United States determined that there have been shifts concerning the effectiveness of lung carcinoma treatment, however, the low survival rate is attributed to a...

Screening Technique Needs Clinical Trials.
January 1, 2000... Spiral CT scanning, a screening technique for early detection of lung cancer, has experts asking for a large clinical trial to determine its potential and promise. Spiral CT scanning is already widely used and scientists claim the technique...

Vitamin E May Prove Beneficial in Disease Progression.
January 1, 2000... A study of the relationship between vitamin E and lung cancer determined there was no benefit from vitamin E for lung cancer patients. However, vitamin E did show promise as a supplement in reducing lung cancer risk. The study was conducted...

Programs Allow Access to Promising but Limited Drugs.
January 1, 2000... I MAGINE YOU HAVE LUNG CANCER. You have tried all available treatments, but you are not getting better. You hear about a new experimental drug and excitedly call your doctor. Sadly, you do not meet the requirements to enter the clinical...

Participating in a Clinical Trial.
January 1, 2000... CANCER PATIENTS ARE UNIQUE IN THAT they are far more likely to participate in a clinical trial. Each new treatment in development represents the hope of a cure or of prolonging one's life and thereby increasing the likelihood of trying new...